Xencor, Inc.
General ticker "XNCR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $906.8M (TTM average)
Xencor, Inc. follows the US Stock Market performance with the rate: 19.0%.
Estimated limits based on current volatility of 4.3%: low 16.42$, high 17.82$
Factors to consider:
- Total employees count: 250 (-10.7%) as of 2024
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Cybersecurity threats, Third-party risks, Clinical trial uncertainties
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [17.03$, 32.00$]
- 2025-12-31 to 2026-12-31 estimated range: [16.03$, 30.61$]
Financial Metrics affecting the XNCR estimates:
- Negative: with PPE of -6.9 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -12.92 <= 0.33
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 71.18 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of -0.50 > -0.66
- Positive: Interest expense per share per price, % of 2.34 <= 3.41
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term XNCR quotes
Long-term XNCR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $164.58MM | $174.62MM | $110.49MM |
| Operating Expenses | $247.05MM | $306.98MM | $288.90MM |
| Operating Income | $-82.47MM | $-132.36MM | $-178.41MM |
| Non-Operating Income | $27.96MM | $12.73MM | $-56.52MM |
| Interest Expense | $0.00MM | $6.18MM | $36.64MM |
| R&D Expense | $199.56MM | $253.60MM | $227.69MM |
| Income(Loss) | $-54.51MM | $-119.63MM | $-234.92MM |
| Taxes | $0.67MM | $13.66MM | $1.62MM |
| Profit(Loss)* | $-55.18MM | $-133.13MM | $-232.62MM |
| Stockholders Equity | $727.50MM | $661.75MM | $677.61MM |
| Assets | $846.27MM | $965.13MM | $951.95MM |
| Operating Cash Flow | $24.48MM | $-77.93MM | $-202.19MM |
| Capital expenditure | $43.40MM | $18.45MM | $6.10MM |
| Investing Cash Flow | $-119.72MM | $-111.06MM | $-7.87MM |
| Financing Cash Flow | $5.70MM | $189.22MM | $197.15MM |
| Earnings Per Share** | $-0.93 | $-2.20 | $-3.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.